242 related articles for article (PubMed ID: 32016901)
21. What Next for Quantum Mechanics in Structure-Based Drug Discovery?
Bryce RA
Methods Mol Biol; 2020; 2114():339-353. PubMed ID: 32016902
[TBL] [Abstract][Full Text] [Related]
22. QM/MM approaches in medicinal chemistry research.
Menikarachchi LC; Gascón JA
Curr Top Med Chem; 2010; 10(1):46-54. PubMed ID: 19929827
[TBL] [Abstract][Full Text] [Related]
23. Machine learning-accelerated quantum mechanics-based atomistic simulations for industrial applications.
Morawietz T; Artrith N
J Comput Aided Mol Des; 2021 Apr; 35(4):557-586. PubMed ID: 33034008
[TBL] [Abstract][Full Text] [Related]
24. Introduction to QM/MM simulations.
Groenhof G
Methods Mol Biol; 2013; 924():43-66. PubMed ID: 23034745
[TBL] [Abstract][Full Text] [Related]
25. Nonempirical energetic analysis of reactivity and covalent inhibition of fatty acid amide hydrolase.
Chudyk EI; Dyguda-Kazimierowicz E; Langner KM; Sokalski WA; Lodola A; Mor M; Sirirak J; Mulholland AJ
J Phys Chem B; 2013 Jun; 117(22):6656-66. PubMed ID: 23654226
[TBL] [Abstract][Full Text] [Related]
26. Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas.
Palermo G; Branduardi D; Masetti M; Lodola A; Mor M; Piomelli D; Cavalli A; De Vivo M
J Med Chem; 2011 Oct; 54(19):6612-23. PubMed ID: 21830831
[TBL] [Abstract][Full Text] [Related]
27. Quantum-Mechanics Methodologies in Drug Discovery: Applications of Docking and Scoring in Lead Optimization.
Crespo A; Rodriguez-Granillo A; Lim VT
Curr Top Med Chem; 2017; 17(23):2663-2680. PubMed ID: 28685695
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Reversibility for Covalent Cysteine Protease Inhibitors Using Quantum Mechanics/Molecular Mechanics Free Energy Surfaces.
Dos Santos AM; Oliveira ARS; da Costa CHS; Kenny PW; Montanari CA; Varela JJG; Lameira J
J Chem Inf Model; 2022 Sep; 62(17):4083-4094. PubMed ID: 36044342
[TBL] [Abstract][Full Text] [Related]
29. Insights in the mechanism of action and inhibition of N-acylethanolamine acid amidase by means of computational methods.
Lodola A; Rivara S; Mor M
Adv Protein Chem Struct Biol; 2014; 96():219-34. PubMed ID: 25443959
[TBL] [Abstract][Full Text] [Related]
30. Understanding the role of carbamate reactivity in fatty acid amide hydrolase inhibition by QM/MM mechanistic modelling.
Lodola A; Capoferri L; Rivara S; Chudyk E; Sirirak J; Dyguda-Kazimierowicz E; Andrzej Sokalski W; Mileni M; Tarzia G; Piomelli D; Mor M; Mulholland AJ
Chem Commun (Camb); 2011 Mar; 47(9):2517-9. PubMed ID: 21240393
[TBL] [Abstract][Full Text] [Related]
31. Protocol for rational design of covalently interacting inhibitors.
Schmidt TC; Welker A; Rieger M; Sahu PK; Sotriffer CA; Schirmeister T; Engels B
Chemphyschem; 2014 Oct; 15(15):3226-35. PubMed ID: 25251382
[TBL] [Abstract][Full Text] [Related]
32. Drug Design in the Exascale Era: A Perspective from Massively Parallel QM/MM Simulations.
Raghavan B; Paulikat M; Ahmad K; Callea L; Rizzi A; Ippoliti E; Mandelli D; Bonati L; De Vivo M; Carloni P
J Chem Inf Model; 2023 Jun; 63(12):3647-3658. PubMed ID: 37319347
[TBL] [Abstract][Full Text] [Related]
33. How exascale computing can shape drug design: A perspective from multiscale QM/MM molecular dynamics simulations and machine learning-aided enhanced sampling algorithms.
Rossetti G; Mandelli D
Curr Opin Struct Biol; 2024 Jun; 86():102814. PubMed ID: 38631106
[TBL] [Abstract][Full Text] [Related]
34. Binding Free Energy Calculation Using Quantum Mechanics Aimed for Drug Lead Optimization.
Cavasotto CN
Methods Mol Biol; 2020; 2114():257-268. PubMed ID: 32016898
[TBL] [Abstract][Full Text] [Related]
35. Model Setup and Procedures for Prediction of Enzyme Reaction Kinetics with QM-Only and QM:MM Approaches.
Glanowski M; Kachhap S; Borowski T; Szaleniec M
Methods Mol Biol; 2022; 2385():175-236. PubMed ID: 34888722
[TBL] [Abstract][Full Text] [Related]
36. The art of atom descriptor design.
Göller AH
Drug Discov Today Technol; 2019 Dec; 32-33():37-43. PubMed ID: 33386093
[TBL] [Abstract][Full Text] [Related]
37. Quantum mechanics implementation in drug-design workflows: does it really help?
Arodola OA; Soliman ME
Drug Des Devel Ther; 2017; 11():2551-2564. PubMed ID: 28919707
[TBL] [Abstract][Full Text] [Related]
38. Quantum mechanical methods for drug design.
Zhou T; Huang D; Caflisch A
Curr Top Med Chem; 2010; 10(1):33-45. PubMed ID: 19929831
[TBL] [Abstract][Full Text] [Related]
39. Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds.
Caballero J; Alzate-Morales JH; Vergara-Jaque A
J Chem Inf Model; 2011 Nov; 51(11):2920-31. PubMed ID: 22011048
[TBL] [Abstract][Full Text] [Related]
40. Effects of the Nature of the Metal Ion, Protein and Substrate on the Catalytic Center in Matrix Metalloproteinase-1: Insights from Multilevel MD, QM/MM and QM Studies.
Varghese A; Chaturvedi SS; DiCastri B; Mehler E; Fields GB; Karabencheva-Christova TG
Chemphyschem; 2021 Dec; 23(4):. PubMed ID: 35991515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
